In Vitro Clinical Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 1.77 M
- Revenue Growth 33.67%
- Profit Growth 36.18%
- Ebitda 34.07%
- Net Worth 319.65%
- Total Assets -5.10%
About In Vitro Clinical Laboratories
In Vitro Clinical Laboratories Private Limited (IVCLPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 December 2014 and has a history of Ten years and two months. Its registered office is in Madurai, Tamil Nadu, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.77 M.
Kalaiyarasi Bothiraj and Bothiraj Vellaichamy serve as directors at the Company.
Company Details
-
Location
Madurai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74900TN2014PTC098360
-
Company No.
098360
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Dec 2014
-
Date of AGM
30 Sep 2017
-
Date of Balance Sheet
31 Mar 2017
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at In Vitro Clinical Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalaiyarasi Bothiraj
|
Director | 08-Dec-2014 | Current |
|
Bothiraj Vellaichamy
|
Director | 08-Dec-2014 | Current |
Financial Performance of In Vitro Clinical Laboratories.
In Vitro Clinical Laboratories Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 33.67% increase. The company also saw a substantial improvement in profitability, with a 36.18% increase in profit. The company's net worth Soared by an impressive increase of 319.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of In Vitro Clinical Laboratories?
In 2017, In Vitro Clinical Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.77 M
₹0
Charges Breakdown by Lending Institutions
- Siemens Financial Services Private Limited : 0.18 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Sep 2015 | Siemens Financial Services Private Limited | ₹1.77 M | Open |
How Many Employees Work at In Vitro Clinical Laboratories?
Unlock and access historical data on people associated with In Vitro Clinical Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of In Vitro Clinical Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped In Vitro Clinical Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.